Akeso Biomedical™ Closes Financing Round of $4.4M

Funding for the Commercial Launch of Feed Additives for Poultry and Piglets to Combat Foodborne Illnesses and Improve Animal Microbiomes

WALTHAM, MA – June 13, 2017 – Akeso Biomedical, Inc., announced today that it closed its most recent financing of $4.4M from existing and new investors. Akeso Biomedical is a privately held company developing novel, non-antibiotic feed additive technologies to improve food safety, animal health and production. Akeso’s feed additives inhibit colonization of animal hosts by bacterial pathogens, thereby reducing the risk of foodborne illness and improving animal performance and value on the farm.

Akeso will use some of the funds to develop manufacturing and global distribution partnerships for TYPLEX™ Chelate, a zootechnical gut health stabilizer which inhibits pathogenic bacteria, such as Clostridium, Campylobacter, Salmonella and E. coli from adhering to avian gut walls. Use of TYPLEX Chelate as a feed additive has been shown in trials to result in an improved gut microbiome in broilers, allowing better nutrient absorption and leading to better performance in the grow-out of chickens, without the use of antibiotics.

In addition, Akeso is pursuing other applications of its Fe3C technology in animal health, including improvements in weaner piglet health, welfare, performance and gut microflora. The funds will also allow the company to progress those initiatives.

Simon Williams, CEO of Akeso Biomedical, said, “We are pleased with the continuing commitment from our existing investors and welcome the new investors in this latest round. We are eager to bring our TYPLEX™ Chelate to market with a strong commercial partner and begin to grow the product categories.”